| Line Item | 2026-03-31 | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $25K | — | — |
| R&D Expense | $1.3M | — | -7.6% |
| SG&A Expense | $1.4M | — | -13.3% |
| Operating Income | -$2.7M | — | +11.5% |
| Net Income | -$2.8M | — | -0.7% |
| EPS (Basic) | -$0.17 | — | +32.0% |
| Line Item | 2026-03-31 | Q/Q | Y/Y |
|---|---|---|---|
| Cash & Equivalents | $19.8M | +34.9% | -21.4% |
| Current Assets | $34.5M | +92.5% | +17.3% |
| Total Assets | $34.9M | +91.3% | +17.5% |
| Current Liabilities | $28.0M | +232.2% | +153.2% |
| Total Liabilities | $28.0M | +232.2% | +153.2% |
| Stockholders' Equity | $6.9M |
| Line Item | 2026-03-31 | Q/Q | Y/Y |
|---|---|---|---|
| Operating Cash Flow | -$4.5M | — | -67.3% |
| Capital Expenditures | $64K | — | — |
| Investing Cash Flow | -$64K | — | — |
| Financing Cash Flow | $19.7M | — | +77.2% |
| Free Cash Flow | -$4.6M | — | -69.7% |
| -62.9% |